Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
Net product revenues for the full-year 2022 are expected to be $843.3 million, a 38% increase over the same period of 2021, which is also expected to exceed SareptaÃs net product revenue guidance of $825 million to 840 million. The expected net product revenues do not include collaboration revenues.